Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss
Home>Topics>>The FDA says J&J's ([[JNJ]] -0.3%) bedaquiline for treating a drug-resistant form of tuberculosis appears to be "safe and well-tolerated," although the highest dose could cause a small change in the ...

The FDA says J&J's ([[JNJ]] -0.3%) bedaquiline for treating a drug-resistant form of tuberculosis appears to be "safe and well-tolerated," although the highest dose could cause a small change in the ...

SeekingAlpha.com: SA Currents

Mon, 26 Nov 2012

The FDA says J&J's ( JNJ -0.3% ) bedaquiline for treating a drug-resistant form of tuberculosis appears to be " safe and well-tolerated ," although the highest dose could cause a small change in the heart's rhythm. J&J is seeking accelerated, temporary approval of bedaquiline; an FDA advisory ...

Read the rest of this article on SeekingAlpha.com: SA Currents

Related Videos

  1. Why J&J Bought a Big Piece of Elan

    Fri, 4 Dec 2009

    Morningstar's Damien Conover and Alex Morozov discuss what J&J's stake in biotech Elan means for both companies.

Content Partners
Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K. Switzerland India Finland
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.